問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Dermatology

Taipei Chang Gung Medical Foundation

Division of Dermatology

更新時間：2023-09-19

張雅菁Chang, Ya-Ching
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

Recruiting Trial

26Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張雅菁

List

44Cases

2026-01-05 - 2028-05-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting7Sites

2026-05-01 - 2027-12-31

Phase II

Active
A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat

  • Condition/Disease

    Subcutaneous Fat

  • Test Drug

    CBL-514

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2027-08-31

Phase II

Active
A single-therapy, multicenter, repeated-dose phase 2 trial was conducted to evaluate the safety of OBI-858 in subjects with moderate to severe frown lines.

  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites

2025-03-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-11-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2024-01-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-06-10 - 2023-09-29

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-11-03 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-01-01 - 2028-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-02-01 - 2024-08-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB